MedTrace Logo

ACTH for Fatigue in Multiple Sclerosis Patients

NCT02315872 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2019-09-09

Study results available
· View outcomes & findings →

Summary

This is a study of Acthar gel (ACTH) in patients with relapsing multiple sclerosis who are experiencing chronic fatigue.

Conditions

  • Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG

ACTH

ACTH injections twice weekly for 28 weeks.

DRUG

Placebo

Placebo injections twice weekly for 28 weeks.

Sponsors & Collaborators

  • Mallinckrodt

    collaborator INDUSTRY

  • Providence Health & Services

    lead OTHER

Principal Investigators

  • Stanely Cohan, MD, PhD · Providence Health & Services

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-22
Primary Completion
2017-06-20
Completion
2018-12-13

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02315872 on ClinicalTrials.gov